Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. - Wikidata - wikimedia - TriplyDB

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

http://www.wikidata.org/entity/Q31081052

about

The use of lentinan for treating gastric cancer Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy Emerging role of S-1 in gastric cancer Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.Treatment options in patients with metastatic gastric cancer: current status and future perspectives Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer.A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.An in vitro study on the effects of the combination of salinomycin with cisplatin on human gastric cancer cells Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results.Capecitabine in advanced gastric cancer.Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma.Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients.Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination.Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction.Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.

P2860

Q24619416-5B42E764-7470-4F85-8C63-06B4E4AFA031 Q24635111-E577EFBF-2A93-413F-9086-BAAA8894D39C Q26774720-EC3796F0-5077-41D9-94ED-D9F8CE997E51 Q33407676-C3D0E1AE-78CC-4CD9-A149-6CE2896FA0CC Q33426501-89477743-FD78-43D7-B912-96834E2AF198 Q34661367-293E62C3-CFDC-4AA3-A18B-32395C796499 Q35002445-0AA08767-8CF0-433A-938A-F3547DB362F6 Q35599748-68FF8F3F-12F5-4F1B-BA9A-48C80621D5DB Q36075265-77E87734-47A2-4013-83FF-DBEA70389DFC Q36153113-A9983CD3-3AC7-4365-BC03-2D33B232D3D8 Q36408904-02123134-5A23-4619-91CD-B3012A4A30FE Q36822873-73659DD3-B383-48CD-AAEC-7BE972970D65 Q36979346-32E1F7B6-A3EC-46EA-8D15-70B359EF50AE Q37077239-31C95E67-9DBD-4592-B7A8-A5859B26703A Q37642780-2120A6B5-33E5-4B7B-B329-C6EE19D6CAA5 Q37703392-014EC182-3641-4E58-93AC-F3AEDCEFF48F Q39470973-AC953A5D-85F2-4951-9CF7-F28E1AF62200 Q41135814-685677D3-D313-4910-B6D2-6EC2489F8676 Q41889228-0F39265C-C2A4-417D-8470-79DE29A2BAF9 Q42181610-D1A01F3C-E4B3-4FA2-939F-5FC904183695 Q42745157-F777E1C5-BA61-4BA6-BC99-1C0302F751BC Q46670683-A0A93BAA-09E4-4D90-9BC0-E3D850B990D5 Q51792653-EFDB42FC-C85B-4790-B26C-A7D821FF84B1 Q55155589-44F70DCF-C9DB-4A8D-A6AB-41F9175F3A15

P2860

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.

http://www.wikidata.org/entity/Q31081052

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Extended safety and efficacy d ...... a multicenter phase II study.

@ast

Extended safety and efficacy d ...... a multicenter phase II study.

@en

type

label

Extended safety and efficacy d ...... a multicenter phase II study.

@ast

Extended safety and efficacy d ...... a multicenter phase II study.

@en

prefLabel

Extended safety and efficacy d ...... a multicenter phase II study.

@ast

Extended safety and efficacy d ...... a multicenter phase II study.

@en

P1433

Q31081052-7CF0E150-55B6-4A0D-8EF5-90EBDD0B05A4

P1476

Q31081052-558B9715-5032-49EF-AD0D-3CA2CF41F925

P2093

Q31081052-29A1538E-7EA2-4E8D-A836-5825ADEFF171

Q31081052-4BB6CD47-B344-4D59-98EC-A9129B5F4B94

Q31081052-5E294D28-2469-49CC-905D-B0B13843835A

Q31081052-62413F8B-3717-4DB6-9243-FD8A45B9884A

Q31081052-86B96817-7371-4048-9EAC-564C81F3503F

Q31081052-A075D3FD-B218-48C8-8242-792C5FD59AB7

Q31081052-A0A31334-F731-4ADE-AADB-79AC471851D6

Q31081052-AB9CC89E-2467-4DD3-8A53-14AE6E0FF45C

Q31081052-B2C61618-2856-4AA9-ABBF-F0F8AC9BA889

P304

Q31081052-F9AAB340-7591-4ACB-A37D-14642FACDF83

P31

Q31081052-C80715F0-48FD-4965-8F18-7E9DDB793FD5

P356

Q31081052-42C5B468-0D9F-439F-8344-AB8B8C1F99EF

P407

Q31081052-B63DD37F-1FAD-45A3-9504-9AAB80B005F8

P433

Q31081052-561E76B9-047E-42D8-9345-12ED0F32412D

P478

Q31081052-8F2535A2-6E23-42CB-9FDE-51E8A6C32B65

P50

Q31081052-05194FFE-D245-4BE4-93D3-88A70282C66A

P577

Q31081052-9F53F496-1618-4E7D-8CD7-656FD2B65D39

P5875

Q31081052-9E156ECB-6779-48D7-8E86-76B690281689

P698

Q31081052-3E0DD889-CDB6-435C-9E31-D0F642858595

P921

Q31081052-506970C6-1CD4-4D3A-9BC9-AE8D2959F5F5

P356

P1433

P1476

Extended safety and efficacy d ...... a multicenter phase II study.

@en

P2093

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Alexandra T Phan

http://www.w3.org/2001/XMLSchema#string

Daniel G Haller

http://www.w3.org/2001/XMLSchema#string

Deepti Singh

http://www.w3.org/2001/XMLSchema#string

Fa-Chyi Lee

http://www.w3.org/2001/XMLSchema#string

Heinz-Joseph Lenz

http://www.w3.org/2001/XMLSchema#string

Jaffer A Ajani

http://www.w3.org/2001/XMLSchema#string

James C Yao

http://www.w3.org/2001/XMLSchema#string

Ronald Yanagihara

http://www.w3.org/2001/XMLSchema#string

P304

33-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22329

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6666014

http://www.w3.org/2001/XMLSchema#string

P698

17133415

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial